3D Imaging Drug Design and Development LLC

Overview

3D Imaging Drug Design and Development LLC is a private biopharmaceutical company that utilizes advanced 3D imaging technology to revolutionize drug design and development. The company is dedicated to improving therapeutic outcomes through innovative research and development processes.

Therapeutic areas

API / Drug Master Files

3D Imaging Drug Design and Development LLC holds 12 active (14 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• Zr89-YS5Active2024-10-01
• I-124 HJAA-F11Active2024-09-17
• ZR89 OXINEActive2021-08-09
• 89 ZR-DARATUMUMABActive2020-12-31
• (F-18) CLOFARABINEActive2020-10-06
• 89ZR-DINUTUXIMABActive2020-07-29
• ZIRCONIUM-89 OXALATEActive2017-02-22
• I-124-MIBG INJECTIONActive2014-10-27
• DPA-713 I 124 INJECTIONActive2013-10-01
• FLUOROMISONIDAZOLE F 18 INJECTIONActive2013-07-19
• SODIUM IODIDE I 124Active2012-03-23
• [I-124] FIAU (FIALURIDINE)Active2010-07-23
• [I-124]CLR1404 INJECTIONInactive2013-12-27
• [F-18] FDPNInactive2010-09-15

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to 3D Imaging Drug Design and Development LLC in our records. PharmaTek screens the full directory against live FDA enforcement data.